Navigation Links
Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
Date:1/11/2012

HOBOKEN, N.J., Jan. 11, 2012 /PRNewswire/-- Octapharma USA today announced that David E. Holliday has joined the biopharmaceutical company as Vice President of Commercial Development, assuming immediate responsibility for all U.S. product marketing, sales and commercial activities and coordination with global portfolio development initiatives.

(Photo:  http://photos.prnewswire.com/prnh/20120111/NY34235 )

Holliday is a senior executive with over 24 years of industry leadership experience, most recently serving as Vice President of Global Marketing Operations & Hemophilia with Baxter Bioscience. Holliday has extensive U.S. and international experience with particular expertise in management, commercial, sales, marketing and business development.

"We are very excited to have David Holliday, a true global leader in our industry, join our senior management team," said Octapharma USA President Flemming Nielsen. "David has critical leadership experience with major multinational pharmaceutical and biotech corporations. He joins Octapharma USA at an extremely important time for our company as our product portfolio in the U.S. will be increasing significantly in the next year and we expect David will be integral to our growth."

Holliday also served as Vice President, Global Marketing Operations and United Kingdom Business Unit Director during his eight years with Baxter Bioscience, which included a number of successful product launches. During his 17-year career with Novartis Pharmaceuticals and Ciba-Geigy Pharmaceuticals, Holliday held progressively responsible management positions, including Business Unit Director of the Transplantation and Mature Products Business Units in the UK.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for nearly 30 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [Human] 5%), is used to treat primary immune deficiencies, and Octapharma's Albumin (Human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® (Von Willebrand Factor/Coagulation Factor VIII Complex [Human]) received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of certain types of Von Willebrand Disease. Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com or www.wilateusa.com.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma Announces octagam® 5% Again Available for U.S. Purchase
2. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
3. Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
4. Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
5. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
6. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
7. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
8. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
11. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... 30, 2016 , ... Shaolin Institute officially starts the annual ... intensive summer training camp starts on June 17th on Shaolin Institute Atlanta Campus. ... a fun and unique experience with an opportunity to learn KungFu martial arts ...
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... SuperCloset is ... all too well the day to day issues, struggles and obstacles veterans’ need to ... Helping Veterans Grow Project provides active or retired military veteran(s) with a donated SuperCloset ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American adults ... that bariatric surgery has received increased attention in recent years, as an article ... comes to weight loss, most people are familiar with the basic requirements of maintaining ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
Breaking Medicine News(10 mins):